

Legends to online Figures

Reference List

- (1) Yoshimoto FK, Guengerich FP. Mechanism of the third oxidative step in the conversion of androgens to estrogens by cytochrome P450 19A1 steroid aromatase. *Journal of the American Chemical Society* 2014;136(42):15016-15025.
- (2) Mahendroo MS, Means GD, Mendelson CR, Simpson ER. Tissue-specific expression of human P-450AROM. The promoter responsible for expression in adipose tissue is different from that utilized in placenta. *Journal of Biological Chemistry* 1991;266(17):11276-11281.
- (3) Hamilton KJ, Hewitt SC, Arao Y, Korach KS. Estrogen Hormone Biology. [Review]. *Current Topics in Developmental Biology* 2017;125:109-146.
- (4) Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell* 1998;95(7):927-937.
- (5) Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. *Journal of Clinical Endocrinology & Metabolism* 2004;89(1):61-70.
- (6) Hewitt KN, Pratis K, Jones ME, Simpson ER. Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. *Endocrinology* 2004;145(4):1842-1848.
- (7) Hewitt SC, Winuthayanon W, Korach KS. What's new in estrogen receptor action in the female reproductive tract. [Review]. *Journal of Molecular Endocrinology* 2016;56(2):R55-R71.
- (8) Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E, Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. *Journal of Clinical Endocrinology & Metabolism* 1978;47(6):1257-1265.
- (9) Santen RJ HI. A comprehensive guide to the therapeutic use of amino-glutethimide. *Pharmanual* , 1-160. 1982. Basael, Karger.
- (10) Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. *Lancet Oncology* 2012;13(5):476-486.

